The AACU Supports Federal Funding for the Kidney Cancer Research Program (KCRP)

“Our study highlights critical gaps in health care equity when it comes to treatments that have been shown effective in prolonging survival,” says Solomon Woldu, MD.

This year, the AACU 2024 Advocacy Summit & Annual Meeting will focus on the intersection of health policy and clinical practice, as well as the impact of current state and national legislative trends on urology.

"Overall, we found that patients with recurrent RCC following adjuvant IO continued to have responses to different types of first-line systemic therapy," says Talal El Zarif, MD.

“The challenge now is to understand how these key aspects of mitochondrial metabolism become activated, why they stimulate metastasis, and whether we can safely block them,” says Ralph J. DeBerardinis, MD, PhD.

"We can individualize the access and the way we do the operation based on the patient's characteristics, and that hasn't happened in a very long time," says Ketan K. Badani, MD.

The grants will support research evaluating ATAD2 in advanced prostate cancer and 6MP in hereditary leiomyomatosis and renal cell cancer.